The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended to delay generic competition. "By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on," FTC Chair Lina Khan said.

The agency sent letters to 10 companies, warning that their patent listings were invalid. It also notified the Food and Drug Administration that it disputes the accuracy and relevance of more than 300 Orange Book patent listings.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.